Product Description
A synthetic small molecule and peptidomimetic of second mitochondrial-derived activator of caspases (SMAC) and inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins, with potential antineoplastic activity. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/birinapant)
Mechanisms of Action: IAP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: TetraLogic
Company Location: PAOLI NY 19301
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Ovarian Cancer|Peritoneal Cancer|NUT Carcinoma|Oncology Solid Tumor Unspecified|Mesothelioma|Colorectal Cancer|Squamous Cell Carcinoma|Esophageal Cancer|Small Cell Lung Cancer|Fallopian Tube Cancer|Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Serous Cystadenocarcinoma|Head and Neck Cancer|Preleukemia|Cholangiocarcinoma|Gastrointestinal Cancer|Cervical Cancer|Juvenile Myelomonocytic Leukemia,|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Acute Myelomonocytic Leukemia
Phase 1: Hepatitis A|Peritoneal Cancer|Hepatitis B, Chronic|Fallopian Tube Cancer|Ovarian Cancer|Lymphoma|Mouth Cancer|Squamous Cell Carcinoma|Head and Neck Cancer|Facial Cancer|Oncology Solid Tumor Unspecified|Nasopharyngeal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2019-00175 | P1 |
Terminated |
Head and Neck Cancer|Nasopharyngeal Cancer|Squamous Cell Carcinoma |
2023-11-15 |
|
| 19-C-0041 | P1 |
Recruiting |
Head and Neck Cancer|Mouth Cancer|Facial Cancer|Squamous Cell Carcinoma |
2020-10-31 |
|
| BPT-201 | P2 |
Terminated |
Cholangiocarcinoma|Head and Neck Cancer|Gastrointestinal Cancer|Squamous Cell Carcinoma|Cervical Cancer|Esophageal Cancer|Mesothelioma|NUT Carcinoma|Colorectal Cancer|Ovarian Cancer|Small Cell Lung Cancer |
2020-02-17 |
|
| HGSOC | P2 |
Withdrawn |
Peritoneal Cancer|Serous Cystadenocarcinoma|Ovarian Cancer |
2020-02-01 |